Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.

doi:10.5604/16652681.1198803

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.

Annals of hepatology - 1 Jan 2000

Jensen Donald M, Asselah Tarik, Dieterich Douglas, Foster Graham R, Sulkowski Mark S, Zeuzem Stefan, Mantry Parvez, Yoshida Eric M, Moreno Christophe, Ouzan Denis, Wright Mark, Morano Luis E, Buynak Robert, Bourlière Marc, Hassanein Tarek, Nishiguchi Shuhei, Kao Jia-Horng, Omata Masao, Paik Seung W, Wong David K, Tam Edward, Kaita Kelly, Feinman S Victor, Stern Jerry O, Scherer Joseph, Quinson Anne-Marie, Voss Florian, Gallivan John-Paul, Böcher Wulf O, Ferenci Peter

Abstract excerpt

INTRODUCTION & AIM: Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1 and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic HCV genotype-1 infection. MATERIAL AND METHODS: Patients were randomized 1:2:2 to receive placebo, faldaprevir 120 mg q.d. (12 or 24 weeks) or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoisobutyric Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Leucine

Share to Oligopeptides

Share to Protease Inhibitors

Share to Quinolines

Share to Randomized Controlled Trials as Topic

Share to Thiazoles

Source

Open in PubMed

Identifiers

PMID: 27049487
DOI: 10.5604/16652681.1198803

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.PMID 27049487Read ↗

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.Semantic proximity Read ↗

SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.Semantic proximity Read ↗

Faldaprevir for the treatment of genotype-1 hepatitis C virus.Semantic proximity Read ↗

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.Semantic proximity Read ↗

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.Semantic proximity Read ↗

Faldaprevir and deleobuvir for HCV genotype 1 infection.Semantic proximity Read ↗

Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.Semantic proximity Read ↗

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.Semantic proximity Read ↗

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.Semantic proximity Read ↗

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.Semantic proximity Read ↗

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.Semantic proximity Read ↗

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.